{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:20:16Z","timestamp":1789676416758,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3-5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1053\/j.seminoncol.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:48:57Z","timestamp":1694652537000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bone-modifying agents for non\u2013small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review"],"prefix":"10.1053","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-9493","authenticated-orcid":false,"given":"Jinyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaiho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghoon","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai Joon","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Kwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Kyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-2380","authenticated-orcid":false,"given":"Jeong Uk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2023.09.002_bib0001","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0002","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0003","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-4975(96)00220-2","article-title":"Distribution of distant metastases from newly diagnosed non-small cell lung cancer","volume":"62","author":"Quint","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin Orthop Relat Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0006","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12885-019-5534-3","article-title":"Clinical analysis of patients with skeletal metastasis of lung cancer","volume":"19","author":"Cho","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0007","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0008","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0009","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.871675","article-title":"The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.21037\/jtd.2016.05.86","article-title":"Outcome of veno-venous extracorporeal membrane oxygenation use in acute respiratory distress syndrome after cardiac surgery with cardiopulmonary bypass","volume":"8","author":"Song","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0013","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","article-title":"Smoking and fracture risk: a meta-analysis","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.chest.2019.06.036","article-title":"Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis","volume":"156","author":"Chen","year":"2019","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0016","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234927","article-title":"Bone metastasis and skeletal-related events in patients with solid cancer: a Korean nationwide health insurance database study","volume":"15","author":"Hong","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0018","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.lungcan.2014.08.022","article-title":"Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study","volume":"86","author":"Cetin","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1634\/theoncologist.2011-0079","article-title":"Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer","volume":"16","author":"Yu","year":"2011","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0021","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0022","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0009-9260(81)80043-8","article-title":"Multiple myeloma: radiology or bone scanning?","volume":"32","author":"Leonard","year":"1981","journal-title":"Clin Radiol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0023","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0024","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/bcr3129","article-title":"PTHrP and breast cancer: more than hypercalcemia and bone metastases","volume":"14","author":"Boras-Granic","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0025","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0026","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/8756-3282(94)90703-X","article-title":"Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer","volume":"15","author":"Taube","year":"1994","journal-title":"Bone"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0027","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0028","doi-asserted-by":"crossref","first-page":"439","DOI":"10.21037\/tlcr-20-835","article-title":"Current progress and mechanisms of bone metastasis in lung cancer: a narrative review","volume":"10","author":"Wu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"G\u00fcl","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1758834014521110","article-title":"Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies","volume":"6","author":"D'Antonio","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0031","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0032","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Acid prostate cancer study, long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e24111","article-title":"Bone-targeting agent utilization among lung cancer patients with bone metastasis in Taiwan","volume":"40","author":"Shih","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0034","first-page":"349","article-title":"Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017","volume":"11","author":"Nakahara","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0035","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0036","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0037","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors: a systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0038","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0039","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10147-010-0179-x","article-title":"Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer","volume":"16","author":"Francini","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","article-title":"Romosozumab for the treatment of osteoporosis","volume":"4","author":"McClung","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0042","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/CORR.0000000000001749","article-title":"Which bone-modifying agent is associated with better outcomes in patients with skeletal metastases from lung cancer? A systematic review and network meta-analysis","volume":"479","author":"Bozzo","year":"2021","journal-title":"Clin Orthop Relat Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0043","first-page":"5223","article-title":"Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany","volume":"28","author":"Diel","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0044","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10198-018-1011-1","article-title":"Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review","volume":"20","author":"Matuoka","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0045","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1016\/j.cllc.2021.03.004","article-title":"Management of oligometastasis and oligoprogression in patients with epidermal growth factor receptor mutation-positive NSCLC in the era of third-generation tyrosine kinase inhibitors","volume":"22","author":"Lim","year":"2021","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2023.09.002_bib0046","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0047","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jrr\/rraa020","article-title":"Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer","volume":"61","author":"Tanaka","year":"2020","journal-title":"J Radiat Res"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0048","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13014-021-01940-0","article-title":"Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study","volume":"16","author":"Makita","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0049","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0050","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100459","article-title":"Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: an exploratory analysis","volume":"37","author":"Pantano","year":"2022","journal-title":"J Bone Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0052","article-title":"Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: a retrospective chart review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0054","doi-asserted-by":"crossref","first-page":"S1028","DOI":"10.1016\/j.annonc.2022.07.1161","article-title":"1035P a phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)","volume":"33","author":"Decroisette","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109030","article-title":"Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer","volume":"110","author":"Zheng","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0056","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","article-title":"Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer","volume":"67","author":"Pandya","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0057","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0058","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0059","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0060","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0061","first-page":"2533","article-title":"Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency","volume":"28","author":"Yang","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0062","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0063","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0064","article-title":"Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases","volume":"16","author":"Dupont","year":"2022","journal-title":"Bone Rep"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","article-title":"Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale","volume":"3","author":"Tyan","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0067","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0068","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/clpt.2011.268","article-title":"Denosumab for the treatment of osteoporosis and cancer-related conditions","volume":"91","author":"Lewiecki","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0069","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3803\/EnM.2022.1429","article-title":"Bone mineral density screening interval and transition to osteoporosis in Asian women","volume":"37","author":"Park","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100423","article-title":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach","volume":"34","author":"Jacobson","year":"2022","journal-title":"J Bone Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0071","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0072","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0073","first-page":"447","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0074","doi-asserted-by":"crossref","first-page":"279","DOI":"10.11005\/jbm.2021.28.4.279","article-title":"Medication related osteonecrosis of the jaw: 2021 position statement of the korean society for bone and mineral research and the Korean Association of Oral and Maxillofacial Surgeons","volume":"28","author":"Kim","year":"2021","journal-title":"J Bone Metab"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11657-020-00761-0","article-title":"Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts","volume":"15","author":"Chalem","year":"2020","journal-title":"Arch Osteoporos"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0076","doi-asserted-by":"crossref","first-page":"167","DOI":"10.11005\/jbm.2015.22.4.167","article-title":"Position statement: drug holiday in osteoporosis treatment with bisphosphonates in South Korea","volume":"22","author":"Lee","year":"2015","journal-title":"J Bone Metab"},{"key":"10.1053\/j.seminoncol.2023.09.002_bib0077","first-page":"1363","article-title":"Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"22","author":"Oster","year":"2014","journal-title":"Support Care Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:49Z","timestamp":1758805069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775423000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":77,"journal-issue":{"issue":"3-5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0093775423000635"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.09.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-modifying agents for non\u2013small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}